Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | HPGDS | O60760 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10314260 | 0.95 | ALDH1A1 (0.38) | ALDH1A1BTKPLA2G2ARAB9ANPC1 | |
| Trifluoroacetic Acid SCHEMBL1061616 | 0.89 | TP53 (0.40) | ALDH1A1KDM4ELMNAPKMTSHR | |
| Trifluoroacetic Acid SCHEMBL1061583 | 0.84 | ALDH1A1 (0.48) | ALDH1A1PLA2G2ANPC1KDM4ELMNA | |
| SCHEMBL10314256 | 0.84 | POLB (0.44) | ALDH1A1RAB9ANPC1LMNAPKM | |
| Trifluoroacetic Acid SCHEMBL1062690 | 0.83 | SIGMAR1 (0.46) | — | |
| SCHEMBL1057380 | 0.82 | ALDH1A1 (0.41) | ALDH1A1BTKRAB9ANPC1KDM4E | |
| Trifluoroacetic Acid SCHEMBL1064358 | 0.82 | ALDH1A1 (0.45) | ALDH1A1KDM4ELMNAPKMTSHR | |
| Trifluoroacetic Acid SCHEMBL1064528 | 0.82 | MAPT (0.44) | ALDH1A1BTKRAB9ANPC1KDM4E | |
| Trifluoroacetic Acid SCHEMBL1062441 | 0.82 | KMT2A (0.46) | ALDH1A1PLA2G2ARAB9AKDM4ELMNA | |
| Trifluoroacetic Acid SCHEMBL1061926 | 0.81 | ALDH1A1 (0.40) | ALDH1A1PLA2G2ANPC1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247588-B1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-8399449-B2 | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-03-19 | — | — | US | disclosed |
| US-8217176-B2 | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20110003788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-06 | — | — | US | disclosed |
| US-20090227561-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | SMO, NR1H2, NR1H4 | ALDH1A1 745/4885BTK 2117/4885PLA2G2A 2527/4885 |
| US-20090227561-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | SMO, NR1H2, NR1H4 | ALDH1A1 776/4885BTK 2228/4885PLA2G2A 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.